Portfolio concentration
As of April 30, 2026 · N-PORT
Holdings
62
Top-10 weight
40.54%
Effective holdings
?
The number of equal-weight positions that would produce this portfolio's concentration (1 ÷ Herfindahl index). A 500-stock fund dominated by a few mega-caps might have only ~100 effective holdings.
21
Crowding
?
The value-weighted average number of funds that also own this fund's positions. High = consensus/crowded picks; low = holdings few other funds own.
466.1
Holdings
As of April 30, 2026 · N-PORT| # | Security | Ticker | Shares | Value | % of fund |
|---|---|---|---|---|---|
| 1 | GOLDMAN FINL SQ TRSRY INST 506 | — | 2,448,306 | $2.45M | 18.99% |
| 2 | US ULTRA BOND CBT Sep25 | — | 1 | $659.87K | 5.12% |
| 3 | DREYFUS GOVT CASH MGMT FUND | DGCXX | 483,278 | $483.28K | 3.75% |
| 4 | ORGANON & CO | — | 26,958 | $357.19K | 2.77% |
| 5 | CORCEPT THERAPEUTICS INC | — | 5,114 | $237.90K | 1.85% |
| 6 | ENLIVEN THERAPEUTICS INC | — | 5,620 | $231.71K | 1.80% |
| 7 | AXSOME THERAPEUTICS INC | — | 1,081 | $224.58K | 1.74% |
| 8 | OMEROS CORP | — | 14,463 | $211.16K | 1.64% |
| 9 | PERRIGO CO PLC | — | 17,588 | $208.24K | 1.62% |
| 10 | DEFINIUM THERAPEUTICS INC | — | 9,260 | $202.61K | 1.57% |
| 11 | NEKTAR THERAPEUTICS | — | 2,353 | $200.10K | 1.55% |
| 12 | TREVI THERAPEUTICS INC | — | 14,451 | $198.85K | 1.54% |
| 13 | TERNS PHARMACEUTICALS INC | — | 3,689 | $195.26K | 1.51% |
| 14 | INDIVIOR PHARMACEUTICALS INC | — | 5,257 | $193.35K | 1.50% |
| 15 | PACIRA BIOSCIENCES INC | — | 7,557 | $192.63K | 1.49% |
| 16 | HARROW INC | — | 4,670 | $189.28K | 1.47% |
| 17 | JAZZ PHARMACEUTI | — | 931 | $189.01K | 1.47% |
| 18 | HARMONY BIOSCIENCES HOLDINGS INC | — | 5,993 | $187.34K | 1.45% |
| 19 | ROYALTY PHARMA-A | — | 3,695 | $185.08K | 1.44% |
| 20 | AMYLYX PHARMACEUTICALS INC | — | 11,556 | $184.90K | 1.43% |
| 21 | VIATRIS INC | — | 12,352 | $184.54K | 1.43% |
| 22 | CRINETICS PHARMACEUTICALS INC | — | 4,666 | $180.95K | 1.40% |
| 23 | ANI PHARMACEUTICALS INC | — | 2,262 | $179.72K | 1.39% |
| 24 | LIGAND PHARMACEUTICALS | — | 780 | $178.97K | 1.39% |
| 25 | MBX BIOSCIENCES INC | — | 5,866 | $177.27K | 1.37% |
| 26 | INNOVIVA INC | — | 7,695 | $176.91K | 1.37% |
| 27 | LIQUIDIA TECHNOLOGIES INC | — | 4,474 | $175.43K | 1.36% |
| 28 | AMNEAL PHARM INC | — | 13,575 | $174.71K | 1.36% |
| 29 | XERIS BIOPHARMA HOLDINGS INC | — | 28,515 | $174.65K | 1.35% |
| 30 | BRISTOL-MYERS SQUIBB CO | — | 2,876 | $174.26K | 1.35% |
| 31 | EDGEWISE THERAPEUTICS INC | — | 5,567 | $172.35K | 1.34% |
| 32 | OCULAR THERAPEUTIX INC | — | 18,162 | $170.18K | 1.32% |
| 33 | PFIZER INC | — | 6,321 | $168.77K | 1.31% |
| 34 | NUVATION BIO INC | — | 37,591 | $167.28K | 1.30% |
| 35 | ZOETIS INC CL A | — | 1,441 | $165.67K | 1.28% |
| 36 | ELANCO ANIMAL HEALTH INC | — | 7,357 | $164.58K | 1.28% |
| 37 | COLLEGIUM PHARMACEUTICAL INC | — | 4,844 | $163.39K | 1.27% |
| 38 | JOHNSON&JOHNSON | — | 710 | $163.19K | 1.27% |
| 39 | MERCK & CO | — | 1,485 | $162.13K | 1.26% |
| 40 | ALUMIS INC | — | 6,551 | $161.74K | 1.25% |
| 41 | LILLY ELI and CO | — | 172 | $160.75K | 1.25% |
| 42 | TARSUS PHARMACEUTICALS INC | — | 2,469 | $157.05K | 1.22% |
| 43 | SUPERNUS PHARMACEUTICALS INC | — | 3,242 | $155.62K | 1.21% |
| 44 | PHIBRO ANIMAL HEALTH CORP CL A | — | 2,911 | $154.81K | 1.20% |
| 45 | EYEPOINT PHARMACEUTICALS INC | — | 11,564 | $152.64K | 1.18% |
| 46 | PRESTIGE CONSUMER HEALTHCARE INC | — | 2,662 | $149.92K | 1.16% |
| 47 | AMPHASTAR PHARMACEUTICALS INC | — | 6,654 | $146.12K | 1.13% |
| 48 | THERAVANCE B | — | 7,856 | $131.51K | 1.02% |
| 49 | PHATHOM PHARMACEUTICALS INC | — | 11,659 | $130.58K | 1.01% |
| 50 | RAPPORT THERAPEUTICS INC | — | 3,931 | $130.23K | 1.01% |
1 / 2
Next ›
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.